相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 The Ivermectin in COVID Nineteen Study
Juliana Cepelowicz Rajter et al.
CHEST (2021)
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study
Jian Wu et al.
CLINICAL INFECTIOUS DISEASES (2020)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
Chih-Cheng Lai et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Arguments in favour of remdesivir for treating SARS-CoV-2 infections
Wen-Chien Ko et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Safety of high-dose ivermectin: a systematic review and meta-analysis
Miriam Navarro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option
Tian-Tian Yao et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Clark D. Russell et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Abdo A. Elfiky
LIFE SCIENCES (2020)
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Kimiyasu Shiraki et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Canrong Wu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Bi-directional differentiation of single bronchioalveolar stem cells during lung repair
Kuo Liu et al.
CELL DISCOVERY (2020)
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Yajing Fu et al.
VIROLOGICA SINICA (2020)
Remdesivir as a possible therapeutic option for the COVID-19
Jaffar A. Al-Tawfiq et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J. -M. Michot et al.
ANNALS OF ONCOLOGY (2020)
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
Achille Aouba et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Markus Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More
Abinit Saha et al.
ARCHIVES OF MEDICAL RESEARCH (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome A Cautionary Case Report
Jared Radbel et al.
CHEST (2020)
Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial
Yuan-Yuan Qin et al.
CHINESE MEDICAL JOURNAL (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
N. Lian et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
Du Yin-Xiao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus
Michele Costanzo et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
Gang Li et al.
HYPERTENSION RESEARCH (2020)
A potential protective role of losartan against coronavirus-induced lung damage
Mehrdad Zeinalian et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2020)
Is teicoplanin a complementary treatment option for COVID-19? The question remains
Giancarlo Ceccarelli et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Teicoplanin: an alternative drug for the treatment of COVID-19?
Sophie Alexandra Baron et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
Sukbin Jang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Lack of antiviral activity of darunavir against SARS-CoV-2
Sandra De Meyer et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19
Jahan S. Khalili et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Tocilizumab treatment in COVID-19: A single center experience
Pan Luo et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Off-label use of tocilizumab in patients with SARS-CoV-2 infection
Simona Di Giambenedetto et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Adewale Bayode Owa et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)
Treatment options for COVID-19: The reality and challenges
Shio-Shin Jean et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
TRIALS (2020)
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Philippe Gautret et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic
Elissa Driggin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
Lei Zha et al.
MEDICAL JOURNAL OF AUSTRALIA (2020)
Interferon-α2b Treatment for COVID-19
Qiong Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?
Athar Khalil et al.
FRONTIERS IN IMMUNOLOGY (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Delayed Initiation of Remdesivir in a COVID-19-Positive Patient
Emily Hillaker et al.
PHARMACOTHERAPY (2020)
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Emanuel Della-Torre et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Antiviral activities of type I interferons to SARS-CoV-2 infection
Emily Mantlo et al.
ANTIVIRAL RESEARCH (2020)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly et al.
ANTIVIRAL RESEARCH (2020)
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ka-Tim Choy et al.
ANTIVIRAL RESEARCH (2020)
Type 1 interferons as a potential treatment against COVID-19
Erwan Sallard et al.
ANTIVIRAL RESEARCH (2020)
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards
Bernard La Scola et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2020)
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Tobias Janowitz et al.
GUT (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)
Yang Song et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Ribavirin therapy for severe COVID-19: a retrospective cohort study
Song Tong et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
Timothee Klopfenstein et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Coagulation disorders in coronavirus infected patients: COVID-19, SARS- CoV-1, MERS-CoV and lessons from the past
Dimitrios Giannis et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19
Marla J. Keller et al.
JOURNAL OF HOSPITAL MEDICINE (2020)
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Angela Patri et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Julien Andreani et al.
MICROBIAL PATHOGENESIS (2020)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
A. B. Cavalcanti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management
Mina T. Kelleni
PHARMACOLOGICAL RESEARCH (2020)
Darunavir does not prevent SARS-CoV-2 infection in HIV patients
Agostino Riva et al.
PHARMACOLOGICAL RESEARCH (2020)
Incidence of thrombotic complications in critically ill ICU patients with COVID-19
F. A. Klok et al.
THROMBOSIS RESEARCH (2020)
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Jonathan A. C. Sterne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis
Arunmozhimaran Elavarasi et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2020)
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin
Urooj Fatima et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2020)
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Kumari G. Lokugamage et al.
JOURNAL OF VIROLOGY (2020)
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
Remo H. M. Furtado et al.
LANCET (2020)
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review
Alexander Fletcher-Sandersjoo et al.
THROMBOSIS RESEARCH (2020)
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
Dhan Bahadur Shrestha et al.
VIROLOGY JOURNAL (2020)
The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
Lucia Gozzo et al.
FRONTIERS IN PHARMACOLOGY (2020)
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Baranca Buijsers et al.
EBIOMEDICINE (2020)
Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study
Qiang Li et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
Katya Uzunova et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study
Qi Tan et al.
BIOORGANIC CHEMISTRY (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
Toru Hifumi et al.
CRITICAL CARE (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Dina B. Mahmoud et al.
JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY (2020)
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Xuhan Zhang et al.
BLOOD ADVANCES (2020)
Clinical trials on drug repositioning for COVID-19 treatment
Sandro G. Viveiros Rosa et al.
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH (2020)
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Bo Ram Beck et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Ribavirin: pharmacology, multiple modes of action and possible future perspectives
Kristina Nystroem et al.
FUTURE VIROLOGY (2019)
Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses
C. E. Hulseberg et al.
JOURNAL OF VIROLOGY (2019)
Darunavir for the treatment of HIV infection
Vincenzo Spagnuolo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
Jan Haviernik et al.
VIRUSES-BASEL (2018)
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
Manabu Aoki et al.
MBIO (2018)
Hydroxychloroquine in systemic lupus erythematosus (SLE)
C. Ponticelli et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Rameshwar U. Kadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Corticosteroids Mechanisms of Action in Health and Disease
Sivapriya Ramamoorthy et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2016)
Icatibant as acute treatment for hereditary angioedema in adults
Henriette Farkas
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Adriaan H. de Wilde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Arbidol as a broad-spectrum antiviral: An update
Julie Blaising et al.
ANTIVIRAL RESEARCH (2014)
Azithromycin: Mechanisms of action and their relevance for clinical applications
Michael J. Parnham et al.
PHARMACOLOGY & THERAPEUTICS (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking
Julie Blaising et al.
ANTIVIRAL RESEARCH (2013)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
P Ward et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)
B Sainz et al.
VIROLOGY (2004)
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
N Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Treatment of SARS with human interferons
J Cinatl et al.
LANCET (2003)
Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin
WS Champney et al.
CURRENT MICROBIOLOGY (2002)
Influenza virus neuraminidase inhibitors
LV Gubareva et al.
LANCET (2000)
分享论文
